Growth Through Specialization, Robust Logistics

Q: What is UCIN Médica’s unique value proposition, and how did it evolve from a medical supplier to become a strategic partner for healthcare institutions?
A: UCIN Médica, founded in 1999 in Guadalajara, focuses primarily on respiratory therapy and anesthesia specialties. Over time, we expanded into other areas such as vascular access and neonatology. Our value proposition lies in our focus on private hospitals, leveraging product specialists, a dedicated sales force, and highly efficient logistics. Our logistics system supports over 300 hospitals, which speaks to our reliability and encourages other hospitals to partner with us. The combination of specialization, trained personnel, and robust logistics constitutes our core value proposition.

Q: What significant events have contributed to UCIN Médica’s recent success?
A: We had extensive experience in these specialties before the pandemic. During the crisis, our positioning strengthened significantly due to increased demand for respiratory equipment. Our clients recognized that we were not improvising, which differentiated us from newer companies that emerged at that time. Our 20-year track record helped us meet the surge in demand, and our logistical and sales teams provided critical support.

We also prioritized protecting our staff with personal protective equipment (PPE) and made donations of PPE to hospitals, which reinforced our credibility and reliability. After the pandemic, the trust we built and the standardization of our services allowed us to maintain and expand our reach. We maintained our pricing and did not sell products outside of our specialization. Maintaining focus and coherence reinforced our credibility with clients.

Q: What changes have you observed in COFEPRIS’s procedures, and how do they affect the introduction of innovative products?
A: Progress remains limited. While some are discussing digitizing and speeding up processes at COFEPRIS, the implementation of those changes is unclear, so significant delays still exist. Regulatory lag continues to be an obstacle for accessing new medical technologies, which ultimately affects access.

Q: How will the company integrate AI and machine learning into its processes?
A: We began considering AI in 2023. Rather than adopting it indiscriminately, we formed an AI committee, identified five key problems to address, and are now evaluating platforms capable of meeting these needs. AI is being integrated into our strategic planning, ensuring it supports defined objectives. By the 1Q26, we plan to have our first AI implementation, purposefully aligned with our business challenges.

Q: What alliances, joint ventures, or mergers is UCIN Médica planning to strengthen its presence in the market?
A: In 2023, we explored multiple expansion strategies, including vertical integration, horizontal acquisitions, and geographic growth. We established a partnership in Costa Rica with Hospimedical, and the main challenge is adapting to the company’s organizational culture. Our partner is a family-run business, which contrasts with our more institutionalized operations. 

When choosing this partner, we evaluated multiple options but found that this company’s cultural fit and business model aligned with our goals. It has a well-developed approach to government sales, complementing our expertise in private healthcare. Additionally, the product mix there allowed for a strategic expansion that combined specialized and commodity products.

Q: How does UCIN Médica contribute to strengthening awareness among healthcare professionals about the proper use of respiratory and anesthetic technologies?
A: Operationally, we focus on users such as physicians, nurses, and technicians through product education and training. We also work with industry leaders, attend events, and maintain relationships with both public and private healthcare executives. We also engage with academia to support early-career professionals through workshops and presentations. Our strategy is comprehensive because hospitals involve multiple decision-makers, from medical staff to procurement and directors.

Q: What objectives does UCIN Médica aim to achieve as it closes 2025?
A: This year has been successful thanks to the acquisition in Costa Rica. In Mexico, success would mean reaching our sales targets and advancing the integration between our Mexican operations and Hospimedical in Costa Rica. We also aim to implement a new ERP system by January 2026, which would mark a major operational milestone.

We aim for the company to last 100 to 200 years. Our legacy will be to continue improving quality of life through our products and contribute meaningfully to the healthcare industry. Institutionalizing our operations not only secures our company’s future but also strengthens the broader healthcare sector by promoting formalization and collaboration. Ultimately, our purpose is to save lives. 

UCIN Médica offers over 800 medical devices from world-leading brands and new technologies related to respiratory therapy and anesthesiology.